首页 社会内容详情
约搏以太坊:Sanofi ends cancer drug trials

约搏以太坊:Sanofi ends cancer drug trials

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

皇冠开户www.hg108.vip)是一个开放皇冠正网即时比分、皇冠开户的平台。皇冠开户平台(www.hg108.vip)提供最新皇冠登录,皇冠APP下载包含新皇冠体育代理、会员APP。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

约搏以太坊www.eth108.vip)采用以太坊区块链高度哈希值作为统计数据,约搏以太坊游戏数据开源、公平、无任何作弊可能性。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
 当前暂无评论,快来抢沙发吧~

发布评论